Acute metformin administration increases mean power and the early Power phase during a Wingate test in healthy male subjects.

The present study tested the hypothesis that acute metformin would increase peak power measured during a Wingate test. Fourteen men (24 ± 6 years; 75.8 ± 10.2 kg; 177 ± 7 cm) participated in four test sessions, conducted in a crossover, counterbalanced, double-blind model. The first and second sessions consisted of anthropometric measurements and one Wingate test per day to assess test-retest reliability. In the last two sessions, the Wingate tests were performed on metformin (500 mg capsule, 1 hour before) or placebo (cellulose capsule, 1 hour before) condition. No differences were found between the placebo and metformin for peak power (1056.8 ± 215.8 W vs. 1095.2 ± 199.3 W, respectively;  = 0.24). Mean power (630.9 ± 87.8 W vs. 613.1 ± 94.8 W, respectively; =0.01) and total work (18928 ± 2633 kJ vs. 18393 ± 2845 kJ, respectively;  = 0.01) in the metformin condition were higher than the placebo. The power were greater in metformin when compared to the placebo in moments 3 ( = 0.01), 4 ( = 0.01), 5 ( = 0.04), 6 ( = 0.04), 7 ( = 0.02), 8 ( = 0.03) and 9 ( = 0.01) seconds. There were no differences between conditions for the peak lactate ( = 0.08) and the rating of perceived exertion ( = 0.84). Acute metformin administration increased the early power phase and the mean power of a Wingate test.